Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Takeshi Kondo, Eri Matsuki, Tomoiku Takaku, Masaya Okada, Kazunori Murai, Chikashi Yoshida, Naoki Watanabe, Naoto Takahashi, Shinya Kimura, Itaru Matsumura

Blood (2023) 142 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2023-174169

Published: 2023

Journal Articles

Allogeneic Donor T Cells Directly Attack Renal Endothelial and Epithelial Cells in Mice

Masahiro Miyata, Eri Matsuki, Yuka Hosokawa, Masahiro Suto, Kazunobu Ichikawa, Dan Peltier, Kenichi Ishizawa, Masafumi Watanabe, Tomomi Toubai

Blood (2022) 140 (Supplement 1): 7332–7333.

https://doi.org/10.1182/blood-2022-158676

Published: 2022

Journal Articles

The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd

Masahiro Suto, Eri Matsuki, Masahiro Miyata, Erika Sekiguchi, Hiroya Tamaki, Isao Tawara, Daniel Peltier, Grace Chen, Kenichi Ishizawa, Pavan Reddy, Tomomi Toubai

Blood (2021) 138 (Supplement 1): 2766.

https://doi.org/10.1182/blood-2021-152089

Published: 2021

Journal Articles

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Masahiro Suto, Eri Matsuki, MD, Erika Sekiguchi, Hiroya Tamaki, MD PhD, Isao Tawara, MD PhD, Grace Chen, MD PhD, Kenichi Ishizawa, MD PhD, Pavan Reddy, Tomomi Toubai

Blood (2019) 134 (Supplement_1): 1926.

https://doi.org/10.1182/blood-2019-123875

Published: 2019

Journal Articles

Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients

Daiki Karigane, MD, Hidenori Kasahara, MD, Masatoshi Sakurai, MD PhD, Eri Matsuki, MD PhD MPH, Keiichi Tozawa, MD, Yuya Koda, MD, Takaaki Toyama, MD, Taku Kikuchi, MD, Jun Kato, MD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Yoko Yatabe, Tomoko Arai, Takayuki Mitsuhashi, MD, Mitsuru Murata, MD PhD, Hiroshi Kobayashi, MD PhD, Keiyo Takubo, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 3061.

https://doi.org/10.1182/blood.V128.22.3061.3061

Published: 2016

Journal Articles

Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma

Santosha A. Vardhana, MD PhD, Neval Ozkaya, MD, Eri Matsuki, MD PhD MPH, Janine D. Pichardo, BS, Alison J. Moskowitz, MD, David J Straus, MD, Amanda R Copeland, RN, MSN, CNS, Ai Ni, PhD, Achim A Jungbluth, MD, Craig H Moskowitz, MD, Ahmet Dogan, MD PhD, Anas Younes, MD

Blood (2016) 128 (22): 1774.

https://doi.org/10.1182/blood.V128.22.1774.1774

Published: 2016

Journal Articles

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Eri Matsuki, MD PhD MPH, Masatoshi Sakurai, MD PhD, Daiki Karigane, MD, Hidenori Kasahara, MD, Taku Kikuchi, MD, Takayuki Shimizu, MD PhD, Kenji Yokoyama, MD PhD, Takehiko Mori, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 1887.

https://doi.org/10.1182/blood.V128.22.1887.1887

Published: 2016

Journal Articles

Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia

Masatoshi Sakurai, MD PhD, Takehiko Mori, MD PhD, Daiki Karigane, MD, Hidenori Kasahara, MD, Keiichi Tozawa, MD, Eri Matsuki, MD PhD MPH, Taku Kikuchi, MD, Jun Kato, MD, Takayuki Shimizu, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 1888.

https://doi.org/10.1182/blood.V128.22.1888.1888

Published: 2016

Journal Articles

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Eri Matsuki, MD, PhD, Taku Kikuchi, MD, Norisato Hashimoto, MD, Shunsuke Souma, MD, Sumiko Kohashi, MD, Takaaki Toyama, MD, Masatoshi Sakurai, MD, Daiki Karigane, MD, Daichi Abe, MD, Takayuki Shimizu, MD, PhD, Kenji Yokoyama, MD, PhD, Hideaki Nakajima, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 1800.

https://doi.org/10.1182/blood.V122.21.1800.1800

Published: 2013

Journal Articles

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Eri Matsuki, MD, PhD, Yukako Ono, MD, Koharu Tonegawa, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Norisato Hashimoto, MD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2012) 120 (21): 2788.

https://doi.org/10.1182/blood.V120.21.2788.2788

Published: 2012

Journal Articles

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Eri Matsuki, MD, PhD, Takashi Kumagai, MD, Koiti Inokuchi, MD, PhD, Kazuteru Ohashi, M.D., Atsushi Shinagawa, MD, PhD, Jin Takeuchi, MD, PhD, Chikashi Yoshida, MD, PhD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kozai, MD, Yukari Shirasugi, MD, Shin Fujisawa, MD, Osamu Iwase, MD, Shingo Yano, MD, Kaichi Nishiwaki, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2012) 120 (21): 691.

https://doi.org/10.1182/blood.V120.21.691.691

Published: 2012

Journal Articles

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

Eri Matsuki, MD, PhD, Yukako Ono, MD, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2011) 118 (21): 3765.

https://doi.org/10.1182/blood.V118.21.3765.3765

Published: 2011

Journal Articles

A Novel Factor XII Mutation, FXII Tokyo (R84P), Causing Factor XII Deficiency In a Patient with Hereditary Spastic Paraplegia

Eri Matsuki, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2010) 116 (21): 1404.

https://doi.org/10.1182/blood.V116.21.1404.1404

Published: 2010

Journal Articles

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

Eri Matsuki, MD, Yoshitaka Miyakawa, MD, PhD, Shuichi Asakawa, Yuiko Tsukada, MD, Kenji Yokoyama, MD, PhD, Jun Kudoh, Shinichiro Okamoto, MD, PhD

Blood (2010) 116 (21): 4451.

https://doi.org/10.1182/blood.V116.21.4451.4451

Published: 2010

Journal Articles

Effectiveness of a Novel Humanized VB22B Minibody against Human TPO Receptor Compared with Recombinant TPO and Eltrombopag Using Primary Human CD34+ Cells and Platelets.

Eri Matsuki, MD, Akiko Yamane, MD, PhD, Shinichiro Okamoto, MD, PhD, Yoshitaka Miyakawa, MD, PhD

Blood (2009) 114 (22): 4559.

https://doi.org/10.1182/blood.V114.22.4559.4559

Published: 2009

Journal Articles

Bortezomib Induces Thrombocytopenia by Inhibiting Proplatelet Formation but Not Proliferation and Endomitosis in Human Primary Megakaryocytes

Wataru Nogami, Akiko Yamane, Takanori Nakamura, Eri Matsuki, Yasuo Ikeda, Yoshitaka Miyakawa

Blood (2008) 112 (11): 87.

https://doi.org/10.1182/blood.V112.11.87.87

Published: 2008

NARROW

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Allogeneic Donor T Cells Directly Attack Renal Endothelial and Epithelial Cells in Mice

The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients

Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

A Novel Factor XII Mutation, FXII Tokyo (R84P), Causing Factor XII Deficiency In a Patient with Hereditary Spastic Paraplegia

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

Effectiveness of a Novel Humanized VB22B Minibody against Human TPO Receptor Compared with Recombinant TPO and Eltrombopag Using Primary Human CD34+ Cells and Platelets.

Bortezomib Induces Thrombocytopenia by Inhibiting Proplatelet Formation but Not Proliferation and Endomitosis in Human Primary Megakaryocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only